Promoter methylation of p16 (INK4A), RASSF1A, and PRSS3 occurs in approximately 30% of cases of bladder cancer; promoter methylation of both RASSF1A and PRSS3 is associated with advanced tumor stage. Here, RASSF1 is linked to urinary bladder carcinoma.